| Fund ID | 805-5277928053 |
| Fund type | Hedge Fund |
| 3(c)(1) exclusion | Yes |
| 3(c)(7) exclusion | No |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | Yes |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| Sales limited to qualified investors | Yes |
| % of assets independently valued | 100% |
| Owned by the adviser or related persons | 53% |
| Owned by funds of funds | 0% |
| Owned by non-U.S. persons | 1% |
| Fund | Type | Gross assets |
|---|---|---|
| Brown Advisory Alternative Strategies, L.P. | Hedge | $433.5M |
| Brown Advisory Global Managers Fund | Hedge | $382M |
| Brown Advisory Global Managers, LLLP - Series C | Hedge | $277.4M |
Ashwood 2021 Global Equity I - Biotech reports $31.9 million in gross assets, among the top 62% of private funds by size.
The stated minimum investment is $50,000.
Ashwood 2021 Global Equity I - Biotech is managed by Brown Advisory Investment Solutions Group LLC.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.